FYERS
Home
/
Stocks
/
Profit Loss
/
Fredun Pharmaceuticals Profit & Loss

Fredun Pharmaceuticals Profit & Loss

Consolidated
Standalone
Quarterly
Yearly
₹
%
Name
Net Revenue
Total Revenue
Total Expenditure
Operating Profit
Interest Expense
PBT
Net Profit
Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025
₹228 Cr₹213 Cr₹161 Cr₹145 Cr₹120 Cr₹167 Cr
₹228 Cr₹213 Cr₹161 Cr₹145 Cr₹120 Cr₹167 Cr
₹199 Cr₹187 Cr₹136 Cr₹125 Cr₹104 Cr₹152 Cr
₹33 Cr₹29 Cr₹26 Cr₹22 Cr₹17 Cr₹17 Cr
₹9 Cr₹14 Cr₹11 Cr₹8 Cr₹7 Cr₹8 Cr
₹21 Cr₹11 Cr₹14 Cr₹13 Cr₹9 Cr₹7 Cr
₹13 Cr₹11 Cr₹10 Cr₹9 Cr₹7 Cr₹6 Cr

Share Price Live Stats

Open (₹)1,524.50
Volume (₹)1,390.00
High (₹)1,524.50
Upper Circuit1,637.00
Low (₹)1,484.00
Lower Circuit1,339.40
Prev Close1,488.20
52W High (₹)1,600.00
Price1,484.00
52W Low (₹)390.57

Share Market Cap & Key Ratios Overview

M.Cap (₹)2461.20 Cr
Div. Yield (%)0.02
PE Ratio56.16
Debt to Equity0.84
Price to Book3.46
Book Value160.92
EPS (TTM)26.50
Face Value10.00
ROE (%)16.09

Stock Analysis (SWOT)

StrengthsWeaknessesOpportunitiesThreats
1. Premium insight available after login
2. Sign in to view full SWOT analysis
3. Unlock strengths, weaknesses, opportunities & threats
Sign in to view
Open a free Demat account in minutes to start investing and screening .
LoginSign Up

QVT

Quality
0/100-
Valuation
0/100-
Technical
0/100-
Sign in to view
Open a free Demat account in minutes to start investing and screening .
LoginSign Up

Peer Stocks

1 week
1 month
1 year
Name
SUNPHARMA-ANSE
DIVISLAB-ANSE
TORNTPHARM-ANSE
ZYDUSLIFE-ANSE
CIPLA-ANSE
LAURUSLABS-ANSE
LUPIN-ANSE
MANKIND-ANSE
DRREDDY-ANSE
AUROPHARMA-ANSE
FREDUN-BNSE
LTP
1W Low
1W High
Market cap (₹)
1901.6-18.5 (-0.96%)
1900.10
1964.85
4,56,833Cr
9186.2-82.8 (-0.89%)
9051.85
9296
2,45,426Cr
4860.1-174.9 (-3.47%)
4858.35
5049
1,87,320Cr
1132.3-54.7 (-4.61%)
1126
1191.45
1,13,217Cr
1380-38 (-2.68%)
1377
1426.20
1,12,212Cr
1853-82.3 (-4.25%)
1812
1947.90
1,01,155Cr
2122.65-52.35 (-2.41%)
2117.80
2209
97,626Cr
2337.45-49.95 (-2.09%)
2323.15
2407.40
96,859Cr
1162.25-15.55 (-1.32%)
1155
1179.90
96,406Cr
1657.65+7.65 (0.46%)
1623.05
1706.70
93,614Cr
1484+6.95 (0.47%)
1433
1529
2,461Cr

Key Highlights of Fredun Pharmaceuticals Ltd’s P&L

In 2026-03-31, Fredun Pharmaceuticals Ltd reported total revenue of ₹639.13Cr, compared with ₹456.27Cr in 2025-03-31, reflecting Fredun Pharmaceuticals Ltd turnover.

Depreciation was ₹8.25Cr and finance costs were ₹39.32Cr in 2026-03-31

Profit Before Tax (PBT) has been ₹47Cr in 2026-03-31 as compared to ₹27.49Cr in 2025-03-31.

Net Profit (PAT) was ₹32.62Cr in 2026-03-31 compared with ₹19.74Cr in 2025-03-31.

Earnings per share (EPS) were ₹59.61 in 2026-03-31, compared with ₹41.80 in 2025-03-31.